Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.2,700.00|
|52 Week High||kr.1,901.50|
|52 Week Low||kr.3,100.00|
|1 Month Change||-9.06%|
|3 Month Change||-0.81%|
|1 Year Change||11.02%|
|3 Year Change||157.14%|
|5 Year Change||136.22%|
|Change since IPO||1,058.80%|
Recent News & Updates
Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 35%?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Genmab A/S ( CPH:GMAB...
With EPS Growth And More, Genmab (CPH:GMAB) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|GMAB||DK Biotechs||DK Market|
Return vs Industry: GMAB matched the Danish Biotechs industry which returned 11.4% over the past year.
Return vs Market: GMAB underperformed the Danish Market which returned 32.7% over the past year.
Stable Share Price: GMAB is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GMAB's weekly volatility (3%) has been stable over the past year.
About the Company
|1999||1,029||Jan van de Winkel||https://www.genmab.com|
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies.
Is Genmab undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GMAB (DKK2700) is trading below our estimate of fair value (DKK4428.7)
Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GMAB is poor value based on its PE Ratio (70.2x) compared to the European Biotechs industry average (25.5x).
PE vs Market: GMAB is poor value based on its PE Ratio (70.2x) compared to the Danish market (15.6x).
Price to Earnings Growth Ratio
PEG Ratio: GMAB is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: GMAB is overvalued based on its PB Ratio (8.7x) compared to the DK Biotechs industry average (6.9x).
How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GMAB's forecast earnings growth (32.3% per year) is above the savings rate (0.1%).
Earnings vs Market: GMAB's earnings (32.3% per year) are forecast to grow faster than the Danish market (8.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GMAB's revenue (22.7% per year) is forecast to grow faster than the Danish market (7.4% per year).
High Growth Revenue: GMAB's revenue (22.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GMAB's Return on Equity is forecast to be low in 3 years time (18.7%).
How has Genmab performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GMAB has a large one-off gain of DKK685.0M impacting its June 30 2021 financial results.
Growing Profit Margin: GMAB's current net profit margins (34.3%) are lower than last year (54.7%).
Past Earnings Growth Analysis
Earnings Trend: GMAB's earnings have grown significantly by 37.8% per year over the past 5 years.
Accelerating Growth: GMAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GMAB had negative earnings growth (-55.6%) over the past year, making it difficult to compare to the Biotechs industry average (19.9%).
Return on Equity
High ROE: GMAB's Return on Equity (12.4%) is considered low.
How is Genmab's financial position?
Financial Position Analysis
Short Term Liabilities: GMAB's short term assets (DKK20.3B) exceed its short term liabilities (DKK1.4B).
Long Term Liabilities: GMAB's short term assets (DKK20.3B) exceed its long term liabilities (DKK880.0M).
Debt to Equity History and Analysis
Debt Level: GMAB is debt free.
Reducing Debt: GMAB has not had any debt for past 5 years.
Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.
What is Genmab current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GMAB's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jan van de Winkel (60 yo)
Dr. Jan G. J. van de Winkel, Ph D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.He is a Co-Founder of Genmab A/S...
CEO Compensation Analysis
Compensation vs Market: Jan's total compensation ($USD5.89M) is above average for companies of similar size in the Danish market ($USD3.60M).
Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.
Experienced Management: GMAB's management team is considered experienced (3.5 years average tenure).
Experienced Board: GMAB's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genmab A/S's employee growth, exchange listings and data sources
- Name: Genmab A/S
- Ticker: GMAB
- Exchange: CPSE
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr.176.531b
- Shares outstanding: 65.38m
- Website: https://www.genmab.com
Number of Employees
- Genmab A/S
- Kalvebod Brygge 43
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 17:03|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.